BiotechTube

SMS995 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome (IBS)

Conditions

Irritable Bowel Syndrome (IBS)

Trial Timeline

Jan 1, 2008 → —

NCT ID
NCT00584298

About SMS995 + Placebo

SMS995 + Placebo is a phase 1 stage product being developed by Novartis for Irritable Bowel Syndrome (IBS). The current trial status is completed. This product is registered under clinical trial identifier NCT00584298. Target conditions include Irritable Bowel Syndrome (IBS).

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00584298Phase 1Completed

Competing Products

20 competing products in Irritable Bowel Syndrome (IBS)

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
52
YM060 + PlaceboAstellas PharmaPhase 3
77
Ramosetron + PlaceboAstellas PharmaApproved
85
Ramosetron + PlaceboAstellas PharmaApproved
85
YM060Astellas PharmaPhase 3
77
YM060 + placeboAstellas PharmaPhase 2
52
YM060Astellas PharmaPhase 3
77
linaclotide + PlaceboAstellas PharmaPhase 3
77
RamosetronAstellas PharmaPre-clinical
23
YM060Astellas PharmaPhase 2
52
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
52
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
52
duloxetineEli LillyApproved
85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
77
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
77
Eluxadoline + PlaceboAbbViePhase 2
52
Placebo + LinaclotideAstraZenecaPhase 3
77
TegaserodNovartisPre-clinical
23
DNK333NovartisPhase 2
52
DNK333 + PlaceboNovartisPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85